🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

24 results for “4D” Clear

  1. 4D-150 IVT (3E10 vg/eye)

    4D Molecular Therapeutics

    Neovascular Age-Related Macular Degeneration (nAMD)

    phase 3 mab active

    1 trial

  2. 4D-150 IVT (3E10 vg/eye)

    4D Molecular Therapeutics

    Macular Neovascularization Secondary to Age-Related Macular Degeneration

    phase 3 mab active

    1 trial

  3. DIFLUPREDNATE, Eylea 40 mg/mL solution for injection in pre-filled syringe, Eylea 40 mg/mL solution for injection in pre-filled syringe, 4D-150, Eylea 40 mg/mL solution for injection in pre-filled syringe, Eylea 40 mg/mL solution for injection in pre-filled syringe

    4D Molecular Therapeutics

    Macular neovascularization secondary to age-related macular degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  4. 4D-125 IVT Injection

    4D Molecular Therapeutics

    X-Linked Retinitis Pigmentosa

    phase 2 mab active

    1 trial

  5. 4D-150 IVT

    4D Molecular Therapeutics

    Neovascular (Wet) Age-Related Macular Degeneration

    phase 2 mab active

    1 trial

  6. 4D-150 IVT

    4D Molecular Therapeutics

    Diabetic Macular Edema

    phase 2 mab active

    1 trial

  7. 4D-310

    4D Molecular Therapeutics

    Fabry Disease

    phase 2 mab active

    2 trials

  8. 4D-710

    4D Molecular Therapeutics

    Cystic Fibrosis Lung

    phase 2 mab active

    1 trial

  9. Blautix

    4D Molecular Therapeutics

    Irritable Bowel Syndrome

    phase 2 mab completed

    1 trial

  10. KEYTRUDA 25 mg/mL concentrate for solution for infusion., MK-3120, ENFORTUMAB VEDOTIN

    Merck Sharp and Dohme

    Urothelial carcinoma

    phase 2 small molecule active

    1 trial

  11. MRx-4DP0004

    4D Molecular Therapeutics

    COVID-19

    phase 2 small molecule terminated

    1 trial

  12. MRx0518

    4D Molecular Therapeutics

    Urothelial Carcinoma

    phase 2 small molecule terminated

    1 trial

  13. MRx0518

    4D Molecular Therapeutics

    Oncology

    phase 2 small molecule terminated

    1 trial

  14. NKTR-102 q14d

    Nektar Therapeutics UK Limited

    Tumor

    phase 2 small molecule completed

    1 trial

  15. 4D-110

    4D Molecular Therapeutics

    Choroideremia

    phase 1 mab active

    1 trial

  16. A trial to learn how safe AZD4063 is, how it moves throughout the body over time, and how it affects the levels of PLN mRNA in adults with dilated cardiomyopathy because of an R14del mutation in the PLN gene

    AstraZeneca AB

    PLN R14del Dilated Cardiomyopathy

    phase 1 other active

    1 trial

  17. Anti-SEMA4D Monoclonal Antibody VX15/2503

    VACCINEX, INC.

    Colon Carcinoma Metastatic in the Liver

    phase 1 mab completed

    1 trial

  18. Anti-SEMA4D Monoclonal Antibody VX15/2503

    VACCINEX, INC.

    Metastatic Melanoma

    phase 1 mab terminated

    1 trial

  19. MRx-4DP0004

    4D Molecular Therapeutics

    Asthma

    phase 1 small molecule terminated

    1 trial

  20. MRx0029

    4D Molecular Therapeutics

    Idiopathic Parkinson Disease

    phase 1 mab terminated

    1 trial

  21. MRx0518

    4D Molecular Therapeutics

    Pancreatic Cancer

    phase 1 small molecule terminated

    1 trial

  22. MRx0518 Capsules

    4D Molecular Therapeutics

    Melanoma

    phase 1 small molecule active

    1 trial

  23. Training with 4D Motion Capture Device

    4D Molecular Therapeutics

    Stroke

    phase 1 other completed

    1 trial

  24. 4D

    4D Molecular Therapeutics

    Dietary Supplementation

    other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources